American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 619-637 , October 2009

Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials

  • Sankar D. Navaneethan, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress correspondence to Sankar D. Navaneethan, MD, MPH, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Ave, Q7, Cleveland, OH 44122
    • ,
  • Suetonia C. Palmer, MBChB
    • ,
  • Jonathan C. Craig, MBChB, PhD
    • ,
  • Grahame J. Elder, PhD
    • ,
  • Giovanni F.M. Strippoli, MD, PhD, MPH, MM

      Affiliations

    • Corresponding Author InformationGiovanni F.M. Strippoli, MD, PhD, MPH, MM, Department of Pharmacology and Clinical Epidemiology, Renal Division, Mario Negri Sud Consortium, S Maria Imbaro (Ch), Italy

Received 13 February 2009 ,Accepted 5 June 2009.

References 

  1. US Renal Data System. USRDS 2008 Annual Data Report (Chapter 11: Costs of End-Stage Renal Disease). http://www.usrds.org/2008/pdf/V2_11_2008.pdfAccessed April 16, 2009
  2. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148–157
  3. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol. 2005;18:5–8
  4. Silver J, Levi R. Cellular and molecular mechanisms of secondary hyperparathyroidism. Clin Nephrol. 2005;63:119–126
  5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  6. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–530
  7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  8. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987–992
  9. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770–779
  10. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005;16(suppl 2):107–114
  11. Fadem SZ, Moe SM. Management of chronic kidney disease mineral-bone disorder. Adv Chronic Kidney Dis. 2007;14:44-43
  12. National Kidney Foundation. Guideline 5: Use of phosphate binders in CKD, in K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Patients. Am J Kidney Dis. 2003;42(suppl 3):S70–S77
  13. Salusky IB. A new era in phosphate binder therapy: What are the options?. Kidney Int Suppl. 2006;105:S10–S15
  14. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23:3167–3175
  15. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286–1291
  16. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement (Quality of Reporting of Meta-analyses). Lancet. 1999;354:1896–1900
  17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias (Dimensions of methodological quality associated with estimates of treatment effects in controlled trials). JAMA. 1995;273:408–412
  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  20. Almirall J, Veciana L, Llibre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol. 1994;14:192–196
  21. Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis. 1998;31:257–262
  22. Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant. 1999;14:1475–1479
  23. Borrego J, Perez del Barrio P, Serrano P, et al. A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis. Nefrologia. 2000;20:348–354
  24. Caravaca F, Santos I, Cubero JJ, et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron. 1992;60:423–427
  25. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17:544–550
  26. d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Sao Paulo Med J. 2000;118:179–184
  27. Phelps KR, Stern M, Slingerland A, Heravi M, Strogatz DS, Haqqie SS. Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure. Am J Nephrol. 2002;22:445–454
  28. Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant. 1994;9:1121–1124
  29. Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: A controlled study. Nephrol Dial Transplant. 1993;8:341–346
  30. Rudnicki M, Hyldstrup L, Petersen LJ, Hojsted J, Transbol I. Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: A randomized double-blind placebo-controlled study. Miner Electrolyte Metab. 1994;20:130–134
  31. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol Dial Transplant. 1991;6:170–175
  32. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification—Results from the BRiC Study. Nephron Clin Pract. 2008;110:c273–c283
  33. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33:694–701
  34. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  35. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–965
  36. Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium (Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients). Clin Nephrol. 1999;51:18–26
  37. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  38. Suki W, Zabaneh R, Cngiano J, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137
  39. DeSanto NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006;199(suppl 9):S108–S114
  40. Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24:278–285
  41. Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19:405–412
  42. Kingusa E, Koshikawa S. Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients—A randomized, open label, dose titration study of PB-94 versus Caltan tablet 500 (calcium carbonate). J Am Soc Nephrol. 2001;12:755A;(abstr)
  43. Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int Suppl. 2003;85:S69–S72
  44. Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial. 2005;9:340–346
  45. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
  46. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261
  47. Sadek T, Mazouz H, Bahlou H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant. 2003;18:582–589
  48. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer (Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients). Saudi Med J. 2004;25:785–791
  49. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride](RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29:66–71
  50. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003;85:S73–S78
  51. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:c8–c19
  52. Shigematsu T Lanthanum Carbonate Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70:404–410
  53. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transplant. 2006;21:2217–2224
  54. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005;20:775–782
  55. Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005;63:461–470
  56. Finn WF, Joy MS, Hladik G Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004;62:193–201
  57. Joy MS, Finn WF LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42:96–107
  58. Malluche HH, Siami GA, Swanepoel C, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol. 2008;70:284–295
  59. Mehrotra R, Martin KJ, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: A multicenter study. Clin J Am Soc Nephrol. 2008;3:1437–1445
  60. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–441
  61. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20:1653–1661
  62. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005;20:764–772
  63. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract. 2006;102:c61–c71
  64. Altmann P, Barnett ME, Finn WF SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71:252–259
  65. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820–825
  66. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445–454
  67. Moe SM, Chertown G. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697–703
  68. Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol. 2006;1:704–709
  69. Bushinsky DA. Phosphate binders: Hold the calcium?. Clin J Am Soc Nephrol. 2006;1:695–696
  70. Silver J. The details bedevil DCOR. Kidney Int. 2007;72:1041–1043
  71. Strippoli GF, Craig JC. Sunset for statins after AURORA?. N Engl J Med. 2009;360:1455–1457
  72. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407
  73. Elder G, Faull R, Branley P, Hawley C. Caring for Australasians with Renal Impairment (CARI) (The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone). Nephrology (Carlton). 2006;11(suppl 1):S230–S261
  74. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther. 2003;10:133–145
  75. Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004;66:1239–1247
  76. Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22:2856–2866
  77. Palmer SC, Craig JC, Strippoli GF. Sevelamer: A promising but unproven drug. Nephrol Dial Transplant. 2007;22:2742–2745
  78. Navaneethan SD, Chaukiyal P, Strippoli GF, Palmer S, Craig J, Elder G. Phosphate binders for preventing and treating bone and cardiovascular disease in chronic kidney disease patients (protocol). Cochrane Database Syst Rev. 2006;2:CD006023
  79. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: We were wrong, time to move on. Lancet. 2007;369:346–350
  80. Strippoli GF, Craig JC. Hypothesis versus association: The optimal hemoglobin target debate. Am J Kidney Dis. 2005;46:970–973
  81. Hutchinson AJ. Oral phosphate binders. Kidney Int. 2009;75:906–914
  82. Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24:601–608
  83. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22:2867–2878

 Originally published online as doi:10.1053/j.ajkd.2009.06.004 on August 19, 2009.

 This review is excerpted from a Cochrane Review to be published in The Cochrane Library (http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME). Cochrane Reviews are regularly updated as new evidence emerges in response to comments and criticisms, and The Cochrane Library should be consulted for the most recent version of the review.

PII: S0272-6386(09)00865-8

doi: 10.1053/j.ajkd.2009.06.004

American Journal of Kidney Diseases
Volume 54, Issue 4 , Pages 619-637 , October 2009

Article Tools

* Image Usage & Resolution